China Biologic Products Holdings Inc, a leading plasma-based biopharmaceutical company in China, received a $3.9 billion counter offer from an investor consortium led by its former CEO, the group said in a release on Monday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?